Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Biotechnology

Healthcare
$31.49 -0.03%

-$0.01 today

Market cap
$3.85B
Beta
0.74
P/E (TTM)
17.3
EPS (TTM)
$1.81
52W Low $19.05High $32.56

Volume 0.00M

Average 2.17M

CPRX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $9.77M rose 3.3% year over year, ahead of the +1.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.5% from the prior quarter. Over 3 fiscal years it compounded at +212.7% a year.

Context

  • Depreciation & amortization amounted to 6.4% of revenue in FY2025, down 1.3 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3.3% holds above the trailing-twelve-month pace of +1.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.77M+2.5% QoQ
Last fiscal yearDec 2025
$37.87M+0.3% YoY
LTMMar 2026
$38.19M+1.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.3%——
1 year+0.3%——
3-year CAGR+212.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
37.87M USD
Year-over-year change
+0.3%
4-year CAGR
+274.8%

Depreciation & Amortization vs competitors

How CPRX compares with its peers on the latest reported figures

  • CPRX's LTM Mar 2026 depreciation & amortization of $38.19M is the 2nd largest of the 9 companies compared; the peer median is $4.93M.
  • Its year-over-year change of +1.0% is the 6th highest of 9, against a peer median of +9.8%.
  • Depreciation & amortization amounts to 6.4% of revenue for CPRX, versus a peer median of 8.0%.
CPRX Competitors Peer median
Depreciation & Amortization for CPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RXRXRecursion Pharmaceuticals, Inc.LTM Jun 2026$78.36M +23.7%+92.4%142.9%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$38.19M +1.0%+212.7%6.4%
BEAMBeam Therapeutics Inc.LTM Jun 2026$22.24M +1.2%+16.4%14.3%
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026$16.13M -11.7%-5.2%5.2%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$5.26M -5.7%-15.4%8.0%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$4.6M +18.5%+29.8%2.0%
KNSAKiniksa Pharmaceuticals, Ltd.LTM Jun 2026$1.79M +19.2%-13.5%0.2%
SRRKScholar Rock Holding CorporationLTM Sep 2026$1.32M -19.2%-17.8%230.7%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$154K +170.2%——
Peer median (excluding CPRX) $4.93M+9.8%-5.2%8.0%

Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income39.48M83.08M71.41M163.89M214.33M
Depreciation & Amortization192K1.24M32.88M37.77M37.87M
Deferred Income Tax9.32M4.94M(17.82M)(9.39M)(6.85M)
Stock-Based Compensation6.07M7.91M14.25M22.25M24.78M
Change in Working Capital5.02M13.73M(37.32M)30.91M(60.9M)
Accounts Receivables(632K)(3.82M)(43.08M)(11.96M)(61M)
Inventory(3.22M)1.07M(4.74M)(3.9M)(18.09M)
Accounts Payables(1.49M)1.21M10.82M1.8M(5.39M)
Other Working Capital10.36M15.28M(330K)44.98M23.59M
Other Non-Cash Items287K5.16M80.2M(5.63M)(563K)
Operating Cash Flow60.37M116.05M143.6M239.81M208.67M
Capital Expenditures(1.02M)(29K)(81.74M)(556K)(58K)
Acquisitions (Net)010M000
Purchases of Investments(10M)(10M)(13.47M)00
Sales of Investments019.24M000
Other Investing Activities0(10M)(279.81M)00
Investing Cash Flow(11.02M)9.21M(293.5M)(556K)(58K)
Debt Repayment00000
Common Stock Issued4.1M9.57M2.79M141M14.67M
Common Stock Repurchased(12.09M)(6.91M)0(296K)(25.3M)
Dividends Paid00000
Other Financing Activities(153K)(968K)(13.65M)(39K)(6.36M)
Financing Cash Flow(8.14M)1.69M(10.86M)140.67M(16.99M)
Effect of Forex Changes00000
Net Change in Cash41.21M126.95M(160.76M)379.92M191.62M
Free Cash Flow59.35M116.02M61.86M239.25M208.61M

Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Intrinsic Alpha fair value

Locked

Current Price

$31.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.